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Background: Soluble Fas (sFas) is a marker of apoptosis that appears to increase in the 
serum of systemic lupus erythematosus patients and may have a correlation with disease activity. 
The exact role of sFas in apoptosis is not clear.  The purpose of this study is to assess the 
correlation between serum levels of soluble Fas (Apo/1-CD95) and the activity of systemic lupus 
erythematosus.  
Patients and Methods: Our study was performed on 114 systemic lupus erythematosus 
patients who were compared with 50 randomly selected sex, age and race-matched healthy 
controls.  Disease activity was defined according to the Systemic Lupus Erythematosus Disease 
Activity Index (SLEDAI-2K). All physical exams and laboratory parameters were collected to 
determine the SLEDAI. sFas levels were determined using a commercially available ELISA kit.   
Results:  There was a significant difference between serum levels of sFas in the case and 
control groups (P=0.001). A significant correlation coefficient existed between the sFas and 
SLEDAI2K variables (P=0.001, r=0.494). Significant statistical difference was found between serum 
levels of sFas in the active and inactive phases of disease according to SLEDAI≤ 9 or ≥10, 
(P=0.002). The sFas levels were 270 – 300 pg/mL for SLEDAI≤9 and 355-502 pg/mL for SLEDAI≥10, 
with a confidence interval of 95%. 
Conclusion: This study shows a significant elevation of sFas levels in the sera of systemic 
lupus erythematosus patients with active disease; therefore it can be used as an appropriate 
marker for evaluation of disease activity. 
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Introduction 
 
ystemic lupus erythematosus (SLE) is an 
autoimmune disease characterized by the 
production of antinuclear antibodies 
(ANAs). Recent research on human and murine 
lupus suggests that disease susceptibility results 
from  impairing  the  clearance  of  apoptotic cells,  
 
 
and increasing apoptosis as well as genetic 
polymorphisms regulating immune responses. 
Because the products of dead cells, including 
nucleic acids, have immunologic activity this 
situation can promote antigen driven ANA 
responses.1  
Fas/APO-1 (CD95) belongs to the tumor 
necrosis factor/nerve growth factor super family. 
Fas and Fas ligand are essential factors in activated 
induced cell death, and any dysfunction in this 
system will lead to a breakdown in peripheral 
tolerance and induction of an autoimmune 
phenomenon.2 
There are different hypotheses regarding the 
role of sFas in activated induced cell death and 
apoptosis.  Some investigators report that during 
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active apoptosis, released sFas may interact with 
FasL, inhibit cellular Fas/FasL interaction and 
therefore inhibit apoptosis, but others postulate that 
sFas is released to exert a pro-apoptogen effect.  
Proussakova and coworkers recently reported that 
sFas antigen can also protect cells against Fas-
mediated apoptosis.  sFas, generated by alternative 
splicing of the intact exon 6, is capable of inducing 
death in transformed cells by "reverse" apoptotic 
signaling via a transmembrane Fas ligand.3 Other 
researchers showed that high levels of sFas in SLE 
patients correlate with leucopenia, tissue and organ 
damage. High serum concentrations of sFas are 
present in an oligomeric form, which demonstrate 
cytotoxicity in a lymphocyte primary culture and 
in transformed cells, while the non-toxic 
recombinant Fas-ligand partially blocks this 
effect.4 On the other hand, most researchers agree 
with the anti-apoptotic effects of sFas.5,6 It is 
known that defects in Fas mediated apoptosis in 
mice lead to autoimmune diseases such as SLE and 
the role of imbalances in apoptosis programs in the 
pathogenesis of SLE is an important hypothesis.6–9 
Some investigators have found a relationship 
between lupus activity and serum sFas levels, 
whereas others did not reach this conclusion.5,10–12  
Therefore, the current study has been designed to 
define the relationship between serum sFas levels 
and the lupus activity index, lupus laboratory tests, 
and to determine if there is a correlation between 
apoptosis markers, particularly sFas levels and 
SLE disease activity. 
 
Patients and Methods 
 
Patients 
In this case control study, 114 SLE patients 
(105 women, 9 men), followed at the 
Rheumatology Department in Ghaem and Imam 
Reza Hospitals, Mashhad University of Medical 
Sciences, were enrolled from May 2006 to June 
2007. The patients were at different stages of the 
disease and diagnosed according to the American 
College of Rheumatology criteria. Using the SLE 
Disease Activity Index (SLEDAI-2K) score,13 
patients were divided into two groups: active (58 
patients) and inactive (56 patients).14,15   
SLEDAI2K is a disease activity index for lupus 
patients consisting of 24 items such as: central 
nervous system, psychological and visual 
disturbances, kidney and skin involvement, fever, 
vasculitis, myositis, serositis, hematologic 
manifestations, and serologic findings such as the 
levels of anti-dsDNA antibodies and complements. 
Definitions of each item were provided on the 
form. Items that present ten days preceding the 
evaluation are noted, and scoring is calculated by 
the sum of the predetermined scores. For items that 
are life threatening, a higher score is noted. 
Possible scores with the SLEDAI2K system vary 
from 0 to 105.13   
For each patient, a clinical data questionnaire 
and past medical histories were first completed.  
Excluded were all pregnant or postpartum patients, 
those with a past or concurrent history of 
malignancy, concurrent infection, smoking or 
addiction, overlapping syndromes, chronic renal 
failure, and other systemic problems not relevant to 
lupus such as a history of hepatitis or liver disease. 
Additionally, we excluded all patients with 
creatinine levels greater than 2 mg/dL or those who 
were on dialysis since a study has shown an 
increase in sFas serum levels during chronic renal 
failure and its negative correlation with creatinine 
clearance.16 
For the control group, 50 healthy age, sex, and 
race-matched volunteer nurses and medical 
students (46 women and 4 men) were selected after 
a health assessment for their present and past 
medical histories and concomitant medications. 
Volunteers with any health problems were 
excluded from our study. This study was approved 
by the Ethics Committee of Mashhad University of 
Medical Science. All participants signed a written 
consent prior to their enrollment in the study. 
 
Methods 
Appropriate samples were collected for 
SLEDAI related laboratory tests. Briefly, 10 mL 
samples of venous blood were obtained and used 
for a complete blood count, determination of ANA 
(immunoflorescence) , anti-dsDNA (ELISA), C3, 
and C4 (nephelometry),  
C-reactive protein (CRP) (Latex agglutination) 
and ESR (1st hour). A random urinalysis and 
measurement of  24-hour urine protein collection 
were also performed. Aliquots of the serum 
samples were stored at -70°C for analysis of sFas. 
All samples were numbered and the laboratory 
personnel were blinded to case and control 
samples. sFas levels were determined using an 
sAPO-1/Fas BMS245 ELISA kit (Bender 
MedsystemsTM, Austria) according to the 
manufacturer’s instructions.  The coefficient of 
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variation (CV): intra-assay precision/inter-assay 
precision for this test was 4.5/3.1%. 
 
Statistical analysis 
Results were expressed as the mean value of 
data±2SD. A P value less than 0.05 was considered 
significant. In order to determine the normal 
distribution of quantitative parameters such as: 
age, C3 and C4, dsDNA, sFas levels, SLEDAI and 
proteinuria, the Kolomogrove-Smirnov test was 
used. For a P value<0.05, nonparametric tests such 
as the Mann Whitney and Kraskal Wallis were 
used. In normal distributed parameters, the t-
student test was the test of choice, and for non 
quantitative variables the Chi-square test was used. 
Since sFas serum level distribution was not 
normal, the Spearman coefficient of correlation 
was used for analysis. 
 
Results 
 
Demographics 
This study was performed on 164 individuals 
(114 patients and 50 healthy controls). The mean 
age of patients was 30.7±9.55 years, the youngest 
was 13 and the oldest was 62. The mean age of 
controls was 29.5±7.21 years, the youngest was 20 
and the oldest was 50. Nine patients and four 
controls were men. The mean duration of disease 
among the patients was four years. There was no 
significant difference between age (P=0.8) and sex 
(P=1) in case and control groups. Patients were at 
different stages of disease activity with or without 
major organ involvement. 
 
Overall laboratory parameters 
Table 1 summarizes important laboratory 
findings such as: sFas levels, anti-ds DNA, C3, C4, 
and serum creatinine for total patients as well as 
active and inactive groups. C3 and C4 normal 
ranges are 70 – 170 mg/dL and 15 – 55 mg/dL, 
respectively. Thirty three patients had a new onset 
proteinuria or an increase in the range of 
proteinuria greater than 0.5 gr/24h (0.5 – 10 gr/24 
h), the mean value was 1.814±1.8 gr/24h.  
Leucopenia was seen in 12 patients (10.5%), 37 
(32.5%) had lymphopenia, and 13 (11.4%) had 
thrombocytopenia. Five patients (4%) had active 
myositis. Creatine phosphokinase and aldolase 
levels in these five patients were two times greater 
than the upper limit of the normal range. 
  
sFas and SLEDAI 
We compared sFas serum levels in the healthy 
group (190.38±127.77 pg/mL) and the SLE 
patients (372.20±228.35 pg/mL) and found a 
significant difference between the levels of these 
two groups (P=0.001) (Figure 1). There was no 
correlation between age and sFas level in the 
patient group (P=0.13).  
The mean SLEDAI for our patients was 
11.97±10.078. Patients were divided into two 
groups according to their SLEDAI; the non-active 
group (SLEDAI≤9) and the active group 
(SLEDAI≥10). The mean sFas serum levels in the 
active and inactive groups were found to be 
significantly different (P=0.001) (Table 1). The 
95% confidence interval for disease activity in 
SLEDAI≤9 was 207 – 303 pg/mL. This range was 
355 – 502 pg/mL for SLEDAI ≥10 (Figure 2).  
When patients were divided into low 
(SLEDAI≤9; 58 patients), medium (SLEDAI≥10 
to ≤30; 50 patients) and high (SLEDAI>30; 6 
patients) activity groups; the sFas mean level 
differed significantly in these three groups 
(P=0.001; Kruskal-Wallis test). 
Next, we evaluated the correlation between 
sFas serum levels and SLEDAI score as a 
quantitative variable. There was a significant 
correlation between the two variables (P=0.001, 
r=0.494) (Figure 3).  
The mean sFas in the control group was 200 
pg/mL, which was close to the reported ranges of 
other references.12,14  In the SLEDAI≤9 group, 
40%, and in the SLEDAI≥10 group, 60% of the 
patients had increased sFas levels of greater than 
Table 1. Comparison of important laboratory parameters in active and inactive groups of SLE patients according to 
SLEDAI2K 
Laboratory 
parameters 
Patient  group 
Mean±2SD Range 
SLEDAI<9 group  
Mean±2SD
SLEDAI≥10 group 
Mean±2SD P-value* 
sFas (pg/mL) 372.20 ±228.35 1–3320 254.82±182.61 493.88±525.57 0.001
anti dsDNA(R**) 4.01± 4.6 1–15.7 3.07±4.5 4.8±4.3 0.002
C3 (mg/dL) 68.64 ±42.78 5–173 84.67±25 51.73±38 0.0001
C4 (mg/dL) 21.15 ±11.6 4–51 25.22±10 16.93±11 0.0001
Creatinine (mg/dL) 0.79± 0.25 0.4–1.5 0.76±0.22 0.83±0.29 0.2
*P values represent the statistical difference between two groups (SLEDAI<9 and SLEDAI≥10) based on Mann-Witney test. **R is the ratio of 
the level of anti dsDNA in each patient to the upper limit of the normal range  
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200 pg/mL. 
 
sFas and other laboratory parameters 
The correlation coefficient between sFas and 
increased 1st hour ESR, was calculated (P=0.003, 
r=0.29). CRP was negative in 63% of the SLE 
patients and positive in 37%. The sFas serum level 
was significantly different in CRP positive and 
CRP negative patients (P=0.027).  There was no 
significant correlation between sFas and C3 
(P=0.511, r=0.06) and sFas and C4 (P=0.582, 
r=0.05). Also, sFas levels were not significantly 
different in patients with normal and decreased C3 
(P=0.3102) or C4 (P=0.9565). We did not find any 
significant correlation between serum levels of 
creatinine and sFas (P=0.13). There was no 
Figure 1. The distribution of soluble FAS level between patients and controls (1=patients, 2=controls) 
Figure 2. The distribution of soluble Fas in active and inactive lupus patients (1=inactive with SLEDAI<9, 2=active with 
SLEDAI≥10) 
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significant correlation between sFas serum levels 
and serum anti ds-DNA, hematuria, sterile pyuria, 
lymphopenia, and thrombocytopenia in the patient 
group.  
 
Major organ involvement 
We evaluated the correlation between sFas 
serum levels and major organ involvement 
(according to SLEDAI score) at the time of the 
study, which has been summarized in Table 2.  
 
sFas and drug history 
Data for medication used was obtained for 
prednisolone according to the dose of the drug, and 
for cytotoxic drugs, according to the type of 
medication used. Among 114 patients, 82.5% were 
on prednisolone. In order to evaluate the 
correlation between sFas serum levels and the 
prednisolone dosage, we classified the patients into 
three groups; prednisolone doses less than 15 mg 
(71%), 16 to 60 mg (26%) and more than 60 mg 
(2.6%). The correlations between sFas levels and 
these three groups were not significant (P=0.16). 
Of all patients, 41% were under 
immunosuppressive therapy with the following 
medications: cyclophosphamide (14%), 
methotrexate (12%), azathioprine (10.5%), and 
mycofenalate mofetil (0.9%). The differences 
between the serum levels of sFas in the patients not 
using and using any type of cytotoxic medication 
was not significant (P=0.800). 
 
Discussion  
 
The role of sFas mediated apoptosis in 
immunity and elimination of autoreactive 
lymphocytes is clear,17 but the function of sFas as a 
marker of apoptosis in autoimmune diseases, 
especially SLE is under investigation.18–20 The 
Figure 3. The regression line of correlation between soluble Fas and SLEDAI 
Table 2. Statistical significance of sFas levels in SLE patients with or without major organ involvement 
Organ involvement Number Subtypes of  each organ involvement P-value* 
Proteinuria** 33 (28.29%) Proteinuria 0.04 
Heart 8 (7%) Pericarditis=7(6.1%) 
Pancarditis=1 (0.9%) 
0.05 
CNS 21 (23.7% ) Seizure=10 (13.9%) 
Psychosis=5 (4.4%) 
CVA=2 (1.8%) 
Vasculitis=2 (1.8%) 
Myasthenia gravis=2 (1.8%) 
0.006 
*P values represent the statistical difference between two groups with and without organ involvement based on Mann-Witney test. **Renal 
involvement was found in 49 patients (based on presence of hematuria, sterile pyuria or proteinuria).  Only patients with proteinuria were included 
in the analysis 
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main goal of this study was to determine the 
correlation between serum levels of sFas and 
disease activity according to SLEDAI. In the first 
step, we had to determine whether there was a 
significant difference in the serum levels of sFas 
between patients and healthy controls. To reach 
this purpose, a case control study was designed and 
a significant statistical difference between cases 
and controls was established. The mean sFas serum 
levels were 190.38±127.77 pg/mL and 
372.20±228.35 pg/mL in controls and patients, 
respectively. The mean values of serum sFas levels 
in healthy individuals reported by different 
investigators were as follows: 220 pg/mL on 40 
blood samples,14 260 pg/mL on 22 samples,12 618 
pg/mL on 20 samples,21 and 2353.4 pg/mL on 15 
samples.15 Different values that were reported for 
mean sFas serum levels might reflect both a 
difference in sample sizes and racial differences. 
Despite controversies on this issue, the normal 
value has been reported from 200 to 2000 pg/mL 
in a more extensive study by Cheng et al.5,22  
Therefore, this range possibly differs with various 
populations and defining an accurate range for 
normal sFas serum level in each geographical 
region would seem necessary in order to perform 
an accurate study. 
This study showed a significant difference in 
the serum level of sFas between the patient and 
healthy groups which confirmed the data as 
reported by Jodo et al.,14 Al-Maini et al.,12 
Courteny et al.,21 and Bijl et al.23  
We also suggest that sFas serum levels are a 
likely marker of the disease activity index. This 
has confirmed previous studies performed by Jodo 
et al.14 and Bijl et al.23 but contradicted data 
reported by Hao et al.,15 Alecu,24 and Al-Maini et 
al.12 In a study by Courteny et al., the correlation 
between sFas and SLEDAI was reported 
significant only during the relapse phase but not 
for the entire course of the disease.21 It is obvious 
that the SLE disease activity score system could be 
affected by different factors.  The scores evaluate 
the patients’ status for a limited time and thus these 
controversies might have originated from the low 
number of patients, medications, and duration of 
activity prior to sampling. 
The coefficient of correlation between sFas and 
SLEDAI was statistically significant. There was no 
significant difference between sFas serum levels in 
males and females of both the patient and control 
groups. Although SLE patients have a particular 
age range; in this study we did not find any 
correlation between age and sFas serum levels in 
SLE patients.  
Although we did not evaluate the SLE damage 
index, however based on the SLEDAI 
questionnaire we found a significant correlation 
between sFas serum levels and major CNS 
involvement. Additionally, we found a significant 
difference between the sFas levels in patients with 
and without active proteinuria. In a study by Hao et 
al., a correlation existed between renal 
involvement and sFas levels.15  
No correlation was found between the serum 
levels of sFas and the use or dosage of 
prednisolone and single or combination 
immunosuppressive therapy. These results 
supported a Sahin et al.,18 study that reported no 
significant difference between serum sFas levels in 
patients on glucocorticoid, immunosuppressive or 
immunomodulatory therapies that were diagnosed 
with different autoimmune diseases and controls, 
who were not treated with these drugs. Although, 
this may be due to the small number of patients 
who did not use prednisolone in our study, it also 
could be a reflection of sampling bias. These drugs 
may decrease the serum levels of sFas via 
apoptosis modulation before decreasing disease 
activity in patients prior to sampling. Based on 
these preliminary results, further investigations 
should be undertaken to discover if sFas levels can 
be used as an independent parameter in 
determination of disease activity  regardless if the 
patient is under treatment or not.   
sFas levels did not correlate with hematological 
abnormalities, anti dsDNA, and C3 and C4 levels, 
but did show a correlation with ESR and positive 
CRP. In a study by Alecu et al., a weak correlation 
has been found between anti dsDNA and sFas.24 
An Al-Maini et al.12 study found no correlation 
between sFas and acute phase reactants while 
Dalboni et al.,16 reported a significant correlation 
between sFas serum levels and serum CRP levels 
in uremic patients. These variations may be related 
to the differences in factors that make a high 
activity score, type of organ involvement and 
medications used prior to sampling.  
Although several studies have been published 
concerning sFas and its role in apoptosis 1,3,4,6,25,26; 
as discussed earlier, the details of this mechanism 
needs more investigation. 
In summary, we have shown that sFas serum 
levels are higher in lupus patients when compared 
to a normal age and sex matched control group, 
and these levels are also higher in active lupus 
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patients when compared with less active patients. 
We have shown a correlation between serum levels 
of sFas, disease activity, and acute phase reactants 
(ESR, CRP). However, the association between 
these factors remains to be studied. 
Further studies are needed to determine if sFas 
elevation is an enhancing factor in apoptosis or if 
sFas works as a suppressor factor that is elevated 
secondary to active apoptosis. Determination of 
sFas levels in new cases prior to treatment with 
prednisolone and immunosuppressive therapy 
would be a valuable study. These patients may be 
followed for sFas level assessment after medical 
therapy. Ultimately, determining the correlation 
between sFas and other apoptotic factors may 
reveal important aspects of apoptosis in lupus 
activity.  
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